Breast_Cancer_Research_Program | Vanderbilt-Ingram Cancer Center

Drivers of breast cancer metastasis

Read more about Drivers of breast cancer metastasis

Overexpression of HER2 (human epidermal growth factor receptor 2) is found in about 25 percent of breast cancers and is associated with poor outcomes. HER2-amplified breast cancers use signaling through a complex of proteins called mTORC2 to drive tumor formation, tumor cell survival and resistance to HER2-targeted therapies. Rebecca Cook, Ph.

Investigators match novel cancer mutations with potential therapies

Read more about Investigators match novel cancer mutations with potential therapies

Research led by Vanderbilt-Ingram Cancer Center (VICC) investigators may have solved a mystery about why a targeted therapy stops working in a small group of breast cancer patients. They identified a novel gene mutation that develops in the tumors, and then found a different cancer drug that appears to treat the newly identified mutation. The […]

Program News

August 10, 2023

New leaders named to Vanderbilt-Ingram research programs

Seven new leaders have been appointed to guide Vanderbilt-Ingram Cancer Center's research programs.

December 15, 2023

Clinical trial shows efficacy for atezolizumab combined with carboplatin

Immunotherapy in combination with chemotherapy has become an important therapeutic treatment option in some patients with metastatic breast cancer. Which patients will benefit the most, however, remains unclear; current biomarkers such as PD-L1 that are used to predict response are mediocre at best.

March 7, 2023

Nicole Kidman and Keith Urban gift supports breast cancer clinical trials at Vanderbilt-Ingram Cancer Center

Nicole Kidman and Keith Urban have made a generous financial gift to Vanderbilt-Ingram Cancer Center in support of clinical trials for new and better therapies for breast cancer.

More Program News

Subscribe to Breast_Cancer_Research_Program